Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:AQST NASDAQ:CLLS NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.50-0.6%$13.88$7.08▼$17.49$322.82M0.8298,955 shs39,244 shsAQSTAquestive Therapeutics$4.20-1.4%$3.38$2.12▼$5.80$423.14M1.971.23 million shs553,143 shsCLLSCellectis$2.00-14.2%$1.57$1.10▼$2.43$129.51M2.91166,101 shs304,110 shsPRTAProthena$6.70-0.9%$5.97$4.32▼$25.42$363.87M0.01962,703 shs717,762 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+2.30%-1.64%+23.73%+39.45%-0.74%AQSTAquestive Therapeutics+7.30%+5.71%+29.48%+49.47%+27.93%CLLSCellectis+25.95%+17.09%+61.81%+54.30%+12.57%PRTAProthena+3.52%+6.96%+11.55%-29.95%-72.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.3786 of 5 stars0.53.00.00.02.40.00.6AQSTAquestive Therapeutics1.4439 of 5 stars3.53.00.00.00.60.00.0CLLSCellectis2.792 of 5 stars3.54.00.00.00.62.50.6PRTAProthena3.9249 of 5 stars4.24.00.00.03.21.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.00Sell$12.00-22.58% DownsideAQSTAquestive Therapeutics 3.00Buy$10.14141.50% UpsideCLLSCellectis 3.00Buy$4.00100.00% UpsidePRTAProthena 2.33Hold$31.50370.15% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, AMRN, AQST, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$7.00 ➝ $12.006/20/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral6/17/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/2/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.005/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.40N/AN/A$23.62 per share0.66AQSTAquestive Therapeutics$57.56M7.25N/AN/A($0.66) per share-6.36CLLSCellectis$49.22M2.26N/AN/A$2.36 per share0.85PRTAProthena$135.16M2.67N/AN/A$9.05 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)AQSTAquestive Therapeutics-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)CLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)PRTAProthena-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)Latest CLLS, AMRN, AQST, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PRTAProthena-$1.06N/AN/AN/AN/AN/A8/5/2025Q2 2025AQSTAquestive Therapeutics-$0.18N/AN/AN/A$11.32 millionN/A8/5/2025N/ACLLSCellectis-$0.15N/AN/AN/A$10.07 millionN/A7/30/2025Q2 2025AMRNAmarin-$0.60N/AN/AN/A$45.45 millionN/A5/12/2025Q1 2025AQSTAquestive Therapeutics-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.532.55AQSTAquestive TherapeuticsN/A4.874.48CLLSCellectis0.441.671.67PRTAProthenaN/A9.009.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%AQSTAquestive Therapeutics32.45%CLLSCellectis63.90%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%AQSTAquestive Therapeutics8.35%CLLSCellectis16.41%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million20.02 millionOptionableAQSTAquestive Therapeutics16099.33 million91.03 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionablePRTAProthena13053.83 million48.88 millionOptionableCLLS, AMRN, AQST, and PRTA HeadlinesRecent News About These CompaniesProthena Corporation plc (NASDAQ:PRTA) Receives $31.50 Consensus Price Target from AnalystsJuly 23 at 2:19 AM | americanbankingnews.comProthena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from AnalystsJuly 20, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?July 12, 2025 | marketbeat.comPRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?July 4, 2025 | zacks.comProthena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average - Should You Sell?July 4, 2025 | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by AnalystsJune 25, 2025 | marketbeat.comProthena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock NewsJune 20, 2025 | gurufocus.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 19, 2025 | finance.yahoo.comProthena Announces Corporate RestructuringJune 18, 2025 | finance.yahoo.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 17, 2025 | msn.comProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | uk.finance.yahoo.comProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | businesswire.comPRTA Prothena Corporation plcJune 7, 2025 | seekingalpha.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 28, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comAnalysts Offer Insights on Healthcare Companies: Prothena (PRTA) and Bristol-Myers Squibb (BMY)May 28, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, AMRN, AQST, and PRTA Company DescriptionsAmarin NASDAQ:AMRN$15.50 -0.09 (-0.58%) Closing price 04:00 PM EasternExtended Trading$15.33 -0.17 (-1.10%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Aquestive Therapeutics NASDAQ:AQST$4.20 -0.06 (-1.41%) Closing price 04:00 PM EasternExtended Trading$4.23 +0.03 (+0.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Cellectis NASDAQ:CLLS$2.00 -0.33 (-14.16%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.02 (+1.25%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Prothena NASDAQ:PRTA$6.70 -0.06 (-0.89%) Closing price 04:00 PM EasternExtended Trading$6.71 +0.01 (+0.15%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
